Table 2.
Comparison of patients with newly diagnosed AML who were either recommended for allo-HCT and proceeded to transplant, or recommended for allo-HCT but did not proceed due to persistent disease
| Characteristic | Overall, N = 1391 |
Proceeded to allo-HCT, N = 105 (76%)1 |
Persistent disease precluding allo-HCT N = 34 (24%)1 |
P value2 |
|---|---|---|---|---|
| Age | 61 (51, 67) | 59 (49, 65) | 63 (56, 71) | 0.016 |
| ELN risk stratification | 0.13 | |||
| Favorable | 20 (14%) | 16 (15%) | 4 (12%) | |
| Intermediate | 41 (29%) | 35 (33%) | 6 (18%) | |
| Adverse | 78 (56%) | 54 (51%) | 24 (71%) | |
| Day 14 bone marrow blast % | > 0.9 | |||
| < 5% | 38 (47%) | 32 (47%) | 6 (46%) | |
| ≥ 5% | 43 (53%) | 36 (53%) | 7 (54%) | |
| Not available | 58 | 37 | 21 | |
| AML subtype | 0.002 | |||
| Therapy-related | 19 (14%) | 14 (13%) | 5 (15%) | |
| AML – other3 | 54 (39%) | 47 (45%) | 7 (21%) | |
| Secondary AML | 10 (7.2%) | 3 (2.9%) | 7 (21%) | |
| AML with MDS related changes | 56 (40%) | 41 (39%) | 15 (44%) |
1
data summarized as median (IQR) and n (%);
2
Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test;
3
AML – other includes AML with recurrent genetic abnormalities and AML, not otherwise specified. ELN, European Leukemia Net; allo-HCT, allogeneic hematopoietic cell transplantation; MDS, myelodysplasia